Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Saniona AB ( (SE:SANION) ) is now available.
Saniona AB, a Copenhagen-based clinical-stage biopharmaceutical company listed on the Nasdaq Stockholm Main Market, develops treatments for neurological and psychiatric disorders, including pipeline assets for paediatric epilepsy, epilepsy, and major depressive disorder. The company advances its portfolio through internal R&D, strategic licensing deals for epilepsy, essential tremor, and obesity therapies, and partnership-ready programs in rare eating disorders and inflammatory bowel disease.
Saniona announced it will host its Q4 and year-end investor call on 26 February 2026 at 11:00 CET, where management will present financial results and provide a broader company update. The event, which includes an online Q&A session and replay access via webcast, offers investors and stakeholders a key opportunity to gauge recent operational progress and the status of its partnered and proprietary clinical programs, potentially informing sentiment around the company’s strategic trajectory and pipeline execution.
The most recent analyst rating on (SE:SANION) stock is a Buy with a SEK30.00 price target. To see the full list of analyst forecasts on Saniona AB stock, see the SE:SANION Stock Forecast page.
More about Saniona AB
Saniona AB is a Copenhagen-headquartered, clinical-stage biopharmaceutical company focused on developing innovative treatments for neurological and psychiatric disorders. Its internal pipeline includes candidates for paediatric epilepsy syndromes, epilepsy, and major depressive disorder, and it has multiple strategic collaborations granting partners rights to programs in epilepsy, essential tremor, and obesity across select global markets.
The company also has two clinical-stage programs available for partnering in rare eating disorders and inflammatory bowel disease, supported by an ion channel discovery platform validated through research collaborations with several major pharmaceutical and biotech partners. Saniona is listed on the Nasdaq Stockholm Main Market, underscoring its role as a publicly traded player in the European biopharma sector.
Average Trading Volume: 983,853
Technical Sentiment Signal: Buy
Current Market Cap: SEK3.45B
Find detailed analytics on SANION stock on TipRanks’ Stock Analysis page.